Chemotherapy remains one of the most vital treatments for cancer, saving millions of lives worldwide, yet it is notorious for its harsh side effects including fatigue, nausea, hair loss, and weakened immunity. Patients and medical experts alike grapple with these challenges, prompting questions about their causes and potential management strategies.
At its core, chemotherapy targets rapidly dividing cells, a defining characteristic of cancer. Dr. Ting Bao, a cancer specialist at the Dana-Farber Cancer Institute in Boston, emphasized its effectiveness in an interview with NIH News in Health, stating, “Chemotherapy does work.” She added, “There are side effects, but they are becoming more and more manageable.”
The drugs used in chemotherapy aim to kill cancer cells or halt their growth, but they inevitably affect healthy cells as well. This occurs because the human body constantly requires new cells to replace old or damaged ones, and some normal cells divide rapidly, much like cancer cells.
Cells lining the intestines and those responsible for hair growth are among the fastest-multiplying in the body. Chemotherapy drugs do not discriminate, attacking these healthy cells too, which leads to common side effects such as nausea from intestinal damage and hair loss from follicle cell destruction.
Another critical impact is on the bone marrow, where blood cells are produced. Damage here reduces the number of red blood cells, resulting in anemia—a condition that causes extreme tiredness and fatigue, exacerbating the physical toll on patients undergoing treatment.
Weakened immunity also stems from this mechanism, as chemotherapy can impair white blood cell production in the bone marrow, leaving patients vulnerable to infections. These side effects highlight the double-edged nature of the therapy, which, while lifesaving, demands careful monitoring and support.
Despite these challenges, advancements in supportive care are making side effects increasingly manageable, as noted by Dr. Bao. Ongoing research and clinical practices at institutions like the Dana-Farber Cancer Institute continue to refine approaches to mitigate the impact on patients' quality of life during cancer treatment.
